Kyverna Therapeutics (KYTX) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free KYTX Stock Alerts $15.47 -0.47 (-2.95%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKyverna Therapeutics (NASDAQ:KYTX) Trading Down 6.6%marketbeat.com - April 25 at 6:18 PMKyverna Therapeutics (NASDAQ:KYTX) Sets New 52-Week Low at $17.70marketbeat.com - April 24 at 6:51 PMKyverna Therapeutics (NASDAQ:KYTX) Stock Price Up 6.4%marketbeat.com - April 22 at 4:46 PMKyverna Therapeutics (NASDAQ:KYTX) Trading Down 2.8%americanbankingnews.com - April 21 at 3:12 AMKyverna Therapeutics (NASDAQ:KYTX) Sees Large Volume Increaseamericanbankingnews.com - April 20 at 6:12 AMKyverna Therapeutics (NASDAQ:KYTX) Shares Down 2.8% marketbeat.com - April 19 at 12:24 PMKyverna Therapeutics (NASDAQ:KYTX) Reaches New 1-Year Low at $21.13americanbankingnews.com - April 19 at 5:36 AMKyverna Therapeutics (NASDAQ:KYTX) Sees Unusually-High Trading Volumemarketbeat.com - April 18 at 12:59 PMKyverna Therapeutics (NASDAQ:KYTX) Hits New 52-Week Low at $21.13marketbeat.com - April 17 at 10:51 AMBuy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Drug Efficacy and Safety Datamarkets.businessinsider.com - April 17 at 10:38 AMBuy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Clinical Advancesmarkets.businessinsider.com - April 17 at 5:37 AMKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseasesfinance.yahoo.com - April 11 at 8:56 PMKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseasesprnewswire.com - April 11 at 5:01 PMKyverna Therapeutics (NASDAQ:KYTX) Trading Up 5.1%marketbeat.com - April 8 at 2:30 PMKyverna Therapeutics (NASDAQ:KYTX) Hits New 12-Month Low at $21.71marketbeat.com - April 3 at 5:31 PMBuy Rating Affirmed for Kyverna Therapeutics on Promising Early-Stage KYV-101 Results for MS Treatmentmarkets.businessinsider.com - April 3 at 10:13 AMKyverna Therapeutics (NASDAQ:KYTX) Shares Up 4.6%marketbeat.com - April 2 at 11:58 AMFirst-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Medfinance.yahoo.com - March 29 at 3:09 PMFirst-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Medprnewswire.com - March 29 at 2:59 PMBuy Recommendation: Kyverna Therapeutics’ Innovative Autoimmune Cell Therapy and Robust Pipeline Promise Market Leadershipmarkets.businessinsider.com - March 29 at 10:09 AMLeerink Partnrs Comments on Kyverna Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:KYTX)marketbeat.com - March 29 at 8:16 AMKyverna Therapeutics (NASDAQ:KYTX) Shares Down 3.5% marketbeat.com - March 27 at 1:42 PMKyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Resultsfinance.yahoo.com - March 27 at 9:46 AMKyverna Therapeutics (NASDAQ:KYTX) Reaches New 12-Month Low at $25.09marketbeat.com - March 25 at 11:53 AMKyverna Therapeutics (NASDAQ:KYTX) Stock Price Up 6.7%marketbeat.com - March 21 at 7:24 PMKyverna Therapeutics (NASDAQ:KYTX) Hits New 1-Year Low at $25.78marketbeat.com - March 19 at 5:40 PMKyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.7%marketbeat.com - March 18 at 4:04 PMWhy That Hot Biotech IPO Could Be a Winnerfinance.yahoo.com - March 14 at 8:36 AMKyverna, Stanford University To Evaluate KYV-101 In Non-Relapsing & Progressive Forms Of MSmarkets.businessinsider.com - March 7 at 11:46 PMHow Kyverna is positioned for success on autoimmune therapy: CEOfinance.yahoo.com - March 7 at 6:46 PMEquities Analysts Offer Predictions for Kyverna Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:KYTX)marketbeat.com - March 6 at 7:31 AMLeerink Partnrs Reiterates "Outperform" Rating for Kyverna Therapeutics (NASDAQ:KYTX)marketbeat.com - March 6 at 7:27 AMKyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up to $27.70marketbeat.com - March 5 at 12:43 PMSVB Leerink Initiates Coverage on Kyverna Therapeutics (NASDAQ:KYTX)marketbeat.com - March 4 at 9:30 AMKyverna Therapeutics Inc KYTXmorningstar.com - February 27 at 2:01 PMKyverna Therapeutics Inc (KYTX)investing.com - February 27 at 1:13 AMEveryone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?msn.com - February 26 at 3:12 PMKyverna Therapeutics Announces Pricing of Upsized Initial Public Offeringfinance.yahoo.com - February 26 at 3:12 PMKyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sharesfinance.yahoo.com - February 26 at 3:12 PM Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address They say it’s ‘unstoppable’ – How I made 43,509% (Ad)Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss. Click here now for the full story. KYTX Media Mentions By Week KYTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYTX News Sentiment▼-0.050.32▲Average Medical News Sentiment KYTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYTX Articles This Week▼44▲KYTX Articles Average Week Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RGNX News CRGX News CGEM News MESO News RLAY News IMTX News BCRX News HLVX News CABA News PROK News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYTX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
